You are here

Merck, Samsung Bioepis launch discounted Remicade alternative


MERCK & CO and South Korea's Samsung Bioepis Co Ltd said on Monday that they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-...

Market voices on: